Research Paper Volume 11, Issue 19 pp 8474—8483

Figure 2. MFSD2A expression and clinical values. (A, B) High expression level of MFSD2A (200×magnification); (C) low expression level of MFSD2A (200×magnification); (D) negative expression of MFSD2A (200×magnification). Low expression of MFSD2A was significantly correlated with tumor grade (E) and stage (F) analyzed with UALCAN database. The lower expression level of MFSD2A represented higher stage and pathological grade. (G) Patients expressing higher levels of MFSD2A show significantly better five-year overall survival (P = 0.021). Survival curves of 79 HCC patients with different MFSD2A expression are shown. Kaplan-Meier survival curves for high expression of MFSD2A group were significantly different (P=0.021, log-rank test) from low MFSD2A expression group in 79 HCC patients. Diagnostic outcomes for plasma MFSD2A in the diagnosis of HCC (H) MFSD2A concentrations in plasma. (I) ROC curve for MFSD2A with HCC versus HC and CHB. MFSD2A=Major Facilitator Superfamily Domain Containing 2A, HCC=hepatocellular carcinoma, CHB=chronic hepatitis B virus infection, HC=healthy control.